Valproic acid-induced hyperammonemia: A case report

Journal of Clinical Psychopharmacology

Volumn 24, Issue 5, 2004, Pages 521-526

  McCall, Mariposa ^a   Bourgeois, James A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBAMAZEPINE; CARNITINE; CODEINE; DIAZEPAM; ESTRADIOL; FLUOROURACIL; LEVOTHYROXINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; SALICYLIC ACID; TOPIRAMATE; TRAZODONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; BRAIN DISEASE; CASE REPORT; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; HUMAN; HYPERAMMONEMIA; MENTAL DISEASE; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; SEIZURE;

AMMONIA; ANTICONVULSANTS; BLOOD UREA NITROGEN; CONSCIOUSNESS DISORDERS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EPILEPSY, POST-TRAUMATIC; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; LIVER FUNCTION TESTS; MENTAL STATUS SCHEDULE; MIDDLE AGED; VALPROIC ACID;

EID: 4644280501     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000138768.61600.ad     Document Type: Review

References (36)

1. Treem W. Inherited and acquired syndromes of hyperammonemia and encephalopathy in children seminars in liver disease. Semin Liver Dis. 1994;14(3):236-258.
2. Montera FJ. Naloxone in the reversal of coma induced by sodium valproate. Ann Emerg Med. 1999;33(3):357-358.
3. Roberge RJ, Francis EH. Use of naloxone in valproic acid overdose: case report and review. J Emerg Med. 2002;22:67-70.
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2): 239-245.
5. Rudolph CD, Rudolph AM, Hostetter MK (Eds.) Inherited urea cycle and related disorders. Rudolph's Pediatrics. 21st ed. New York: McGraw Hill Medical Publishing Division. 2003:618-631.
6. Verrotti A, Trotta D, Morgese G, et al. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002;17(4):367-373.
7. Takahashi H, Brusilow SW, Koehler RC, et al. Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic rats. Am J Physiol. 1991;261:H825-829.
8. Champe PC, Harvey RA. Lippincott's Illustrated Reviews: Biochemistry. 2nd ed. Philadelphia: JB Lippincott Company. 1994:229-242.
9. Laub M, Paetzke-Brunner I, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia. 1986;27:559-562.
10. Murakami K, Sugimoto T, Nishida N, et al. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy. Brain Dev. 1992;14:178-181.
11. Llansola M, Erceg S, Hernández M, et al. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms. Metab Brain Dis. 2002;17(4):389-397.
12. Stadler DD, Bale JF, Chenard CA, et al. Effect of long-term valproic acid administration on the efficiency of carnitine reabsorption in humans. Metabolism. 1999;48(1):74-79.
13. Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother. 2000;34(5):630-638.
14. Suárez I, Bodega G, Fernández B. Glutamine synthetase in brain: effect of ammonia. Neurochem Int. 2002;41(2-3):123-142.
15. Oechsner M, Steen C, Stürenburg HJ, et al. Hyperammonemic encephalopathy after initiation of valproate therapy in unrecognized ornithine transcarbamoylase deficiency. J Neurol Neurosurg Psychiatry. 1998;64:680-682.
16. Brusilow SW. Hyperammonemic encephalopathy. Medicine. 2002;81:240-249.
17. 1H MR spectroscopy. Epilepsia. 2002;43(9):1101-1106.
18. Felipo V, Butterworth RF. Neurochemistry of ammonia. Neurochem Int. 2002;41(2-3)79-80.
19. Depakote Tablets Package Insert. Abbott Pharmaceutical Products Division. May 2002.
20. Zaret BS, Beckner RR, Marini AM, et al. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology. 1982;32:206-208.
21. Felig DM, Brusilow SW, Boyer JL. Hyperammonemic coma due to parental nutrition in a woman with heterozygous ornithine transcarbamoylase deficiency. Gastroenterology. 1995;109:282-284.
22. Gidal BE, Inglese CM, Meyer JF, et al. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol. 1997;16(4):301-305.
23. Wraith JE. Ornithine carbamoylase deficiency. Arch Dis Child. 2001;84:84-93.
24. Schimanski U, Krieger D, Horn M, et al. A novel two-nucleotide deletion in the ornithine transcarbamoylase gene causing fatal hyperammonemia in early pregnancy. Hepatology. 1996;24:1413-1415.
25. Yeh KH, Cheng AL. High dose 5-fluorouracil infusional therapy is associated with hyperammonemia, lactic acidosis and encephalopathy. Br J Cancer. 1997;75:464-465.
26. Makela AL, Lang H, Korpela P. Toxic encephalopathy with hyperammonemia during high dose salicylate therapy. Acta Neurol Scand. 1980;61:146-156.
27. Vossler DG, Wilensky AJ, Cawthon DF, et al. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia. 2002;43(2):154-159.
28. Duarte J, Macias S, Coria F, et al. Valproate-induced coma: case report and literature review. Ann Pharmacother. 1993;27:582-583.
29. Hamer HM, Knake S, Schomburg U, et al. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000;54:230-232.
30. Maestri NE, Brusilow SW, Clissold DB, et al. Long term treatment of girls with ornithine transcarbamoylase deficiency. N Engl J Med. 1996;335(12):855- 860.
31. Eze E, Workman M, Donley B. Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. Psychiatr Serv. 1998;49:1358-1359.
32. Barrueto F, Hack JB. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy. Acad Emerg Med. 2001;8(10):999-1001.
33. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproic-induced hepatotoxicity. Neurology. 2001;56:1405-1409.
34. DeVivo DC, Bohan TP, Coulter DL, et al. L-Carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia. 1998;39(11): 1216-1225.
35. Altunbasak S, Baytok V, Tasouji M, et al. Asymptomatic hyperammonemia in children treated with valproic acid. J Child Neurol. 1997;12:461-463.
36. Hawkes ND, Thomas GA, Jurewicz A, et al. Non-hepatic hyperammonemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J. 2001;77:717-722.